162 related articles for article (PubMed ID: 29469765)
1. Nivolumab reactivation of hypertrophic lichen planus, a case report and review of published literature.
Maarouf M; Alexander C; Shi VY
Dermatol Online J; 2018 Jan; 24(1):. PubMed ID: 29469765
[TBL] [Abstract][Full Text] [Related]
2. FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.
Kazandjian D; Suzman DL; Blumenthal G; Mushti S; He K; Libeg M; Keegan P; Pazdur R
Oncologist; 2016 May; 21(5):634-42. PubMed ID: 26984449
[TBL] [Abstract][Full Text] [Related]
3. Nivolumab: a review in advanced squamous non-small cell lung cancer.
Keating GM
Drugs; 2015 Nov; 75(16):1925-34. PubMed ID: 26514815
[TBL] [Abstract][Full Text] [Related]
4. Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report.
Li H; Ma W; Yoneda KY; Moore EH; Zhang Y; Pu LL; Frampton GM; Molmen M; Stephens PJ; Li T
J Hematol Oncol; 2017 Feb; 10(1):64. PubMed ID: 28245875
[TBL] [Abstract][Full Text] [Related]
5. Diffuse lichen planus-like keratoses and clinical pseudo-progression associated with avelumab treatment for Merkel cell carcinoma, a case report.
Cardis MA; Jiang H; Strauss J; Gulley JL; Brownell I
BMC Cancer; 2019 Jun; 19(1):539. PubMed ID: 31164102
[TBL] [Abstract][Full Text] [Related]
6. Anti-PD-1-related cryoglobulinemia during treatment with nivolumab in NSCLC patient.
Pellegrino B; Musolino A; Tiseo M
Ann Oncol; 2017 Jun; 28(6):1405-1406. PubMed ID: 28383638
[No Abstract] [Full Text] [Related]
7. Oral lichenoid reaction showing multiple ulcers associated with anti-programmed death cell receptor-1 treatment: A report of two cases and published work review.
Obara K; Masuzawa M; Amoh Y
J Dermatol; 2018 May; 45(5):587-591. PubMed ID: 29352490
[TBL] [Abstract][Full Text] [Related]
8. The safety and efficacy of nivolumab in advanced (metastatic) non-small cell lung cancer.
Tanvetyanon T; Creelan BC; Antonia SJ
Expert Rev Anticancer Ther; 2016 Sep; 16(9):903-10. PubMed ID: 27488231
[TBL] [Abstract][Full Text] [Related]
9. Nivolumab-induced lichen planus pemphigoides.
Strickley JD; Vence LM; Burton SK; Callen JP
Cutis; 2019 Apr; 103(4):224-226. PubMed ID: 31116807
[TBL] [Abstract][Full Text] [Related]
10. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
Godwin JL; Jaggi S; Sirisena I; Sharda P; Rao AD; Mehra R; Veloski C
J Immunother Cancer; 2017; 5():40. PubMed ID: 28515940
[TBL] [Abstract][Full Text] [Related]
11. Development of psoriatic arthritis during nivolumab therapy for metastatic non-small cell lung cancer, clinical outcome analysis and review of the literature.
Ruiz-Bañobre J; Pérez-Pampín E; García-González J; Gómez-Caamaño A; Barón-Duarte FJ; López-López R; Vázquez-Rivera F
Lung Cancer; 2017 Jun; 108():217-221. PubMed ID: 28625638
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
Brahmer J; Reckamp KL; Baas P; Crinò L; Eberhardt WE; Poddubskaya E; Antonia S; Pluzanski A; Vokes EE; Holgado E; Waterhouse D; Ready N; Gainor J; Arén Frontera O; Havel L; Steins M; Garassino MC; Aerts JG; Domine M; Paz-Ares L; Reck M; Baudelet C; Harbison CT; Lestini B; Spigel DR
N Engl J Med; 2015 Jul; 373(2):123-35. PubMed ID: 26028407
[TBL] [Abstract][Full Text] [Related]
13. PD-1 inhibitors induced bullous lichen planus-like reactions: a rare presentation and report of three cases.
Wakade DV; Carlos G; Hwang SJ; Chou S; Hui R; Fernandez-Peñas P
Melanoma Res; 2016 Aug; 26(4):421-4. PubMed ID: 27135655
[TBL] [Abstract][Full Text] [Related]
14. The safety of nivolumab for the treatment of advanced non-small cell lung cancer.
Metro G; Ricciuti B; Brambilla M; Baglivo S; Soli I; Minenza E; Leonardi GC; D'arpino A; Colabrese D; Tazza M; Zicari D; Minotti V; Chiari R
Expert Opin Drug Saf; 2017 Jan; 16(1):101-109. PubMed ID: 27910704
[TBL] [Abstract][Full Text] [Related]
15. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.
Rizvi NA; Mazières J; Planchard D; Stinchcombe TE; Dy GK; Antonia SJ; Horn L; Lena H; Minenza E; Mennecier B; Otterson GA; Campos LT; Gandara DR; Levy BP; Nair SG; Zalcman G; Wolf J; Souquet PJ; Baldini E; Cappuzzo F; Chouaid C; Dowlati A; Sanborn R; Lopez-Chavez A; Grohe C; Huber RM; Harbison CT; Baudelet C; Lestini BJ; Ramalingam SS
Lancet Oncol; 2015 Mar; 16(3):257-65. PubMed ID: 25704439
[TBL] [Abstract][Full Text] [Related]
16. Bullous lichen planus and anti-programmed cell death-1 therapy: Case report and literature review.
de Lorenzi C; André R; Vuilleumier A; Kaya G; Abosaleh M
Ann Dermatol Venereol; 2020 Mar; 147(3):221-227. PubMed ID: 31982173
[TBL] [Abstract][Full Text] [Related]
17. Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable.
Prasad V; Kaestner V
Semin Oncol; 2017 Apr; 44(2):132-135. PubMed ID: 28923211
[TBL] [Abstract][Full Text] [Related]
18. Use of the PD-1 Pathway Inhibitor Nivolumab in a Renal Transplant Patient With Malignancy.
Boils CL; Aljadir DN; Cantafio AW
Am J Transplant; 2016 Aug; 16(8):2496-7. PubMed ID: 26988410
[No Abstract] [Full Text] [Related]
19. Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer.
Rossi E; Sgambato A; De Chiara G; Casaluce F; Losanno T; Sacco PC; Santabarbara G; Gridelli C
Expert Rev Clin Pharmacol; 2016; 9(3):419-28. PubMed ID: 26681547
[TBL] [Abstract][Full Text] [Related]
20. Vitiligo in a patient with lung adenocarcinoma treated with nivolumab: A case report.
Uenami T; Hosono Y; Ishijima M; Kanazu M; Akazawa Y; Yano Y; Mori M; Yamaguchi T; Yokota S
Lung Cancer; 2017 Jul; 109():42-44. PubMed ID: 28577948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
